Gelesis Holdings Inc (GLSHQ)
Gelesis Holdings Inc. is a healthcare company whose common stock has been quoted on OTC Markets under the symbol GLSH.Q. The company was described as a commercial-stage biotherapeutics business focused on approaches intended to address obesity and gastrointestinal-related chronic conditions. Its portfolio included PLENITY, an orally administered, non-stimulant, non-systemic aid for weight management, along with development programs such as GS200 for weight loss in prediabetes and type 2 diabetes, GS500 for functional constipation, and the pre-clinical GS300 for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Incorporated in 2006 and based in Boston, Massachusetts, Gelesis Holdings and its affiliates filed a voluntary Chapter 7 liquidation petition on October 30, 2023.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-GLSH.Q
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
—
|
—
|
—
|
0.073 K
|
—
|
—
|
—
|
—
|
—
|
—
|